Exclusive Summary

• Leverage the prestigious US-FDA GMP certification and ANDA approval to fast-track registration in emerging markets (SEA, LatAm, MENA) that accept the US as a Reference Reference Country.
• The 28mg Extended-Release (ER) formulation offers a critical 'Once-Daily' clinical advantage over generic Immediate-Release (IR) tablets, significantly improving adherence in Alzheimer's patients and creating a product upgrade opportunity for partners.
• Capitalize on the massive demand driven by the global aging population with a solution that combines the cost-efficiency of Chinese manufacturing with top-tier US quality standards.